Studying DNA changes in small cell lung cancer during treatment
Part of Cancer, Lungs & breathing clinical trials.
This trial looks at how DNA in your blood changes over time when you receive chemotherapy combined with immunotherapy for extensive-stage small cell lung cancer. The goal is to better understand how the cancer evolves during first-line treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with small cell lung cancer that has spread (extensive stage).
- You are about to start your first treatment with chemotherapy plus immunotherapy, as decided by your doctors.
- You are 18 years or older.
- You are able to understand and follow the study procedures.
- You are covered by French social security and are treated at Cochin Hospital or HEGP in Paris.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial collects blood and tumor samples from people newly diagnosed with small cell lung cancer to study how genetic markers can predict treatment success and monitor disease over time.
This trial tests a new study drug (PF08634404) combined with standard chemotherapy for people whose non-small cell lung cancer has changed into a more aggressive form called small cell lung cancer. It hopes to improve outcomes by targeting the cancer in two ways.
This study uses a lab test called “proteomics” to learn more about newly diagnosed small cell lung cancer (SCLC). It may help researchers understand the disease better and improve future treatment decisions, while participants also receive standard chemotherapy.
This observational study collects information and lab samples from people with extensive-stage small cell lung cancer. It may help researchers understand how patients respond and improve future care, but it usually does not add new treatment for you.
This study looks at genetic markers in two types of lung cancer (small cell and large cell neuroendocrine) to understand why some tumors stop responding to a standard treatment that combines chemotherapy with immunotherapy. If you have one of these cancers and are about to start this treatment, you may be able to join.
This study looks at immune-related blood/tissue markers to understand disease activity in people with extensive-stage small cell lung cancer after standard upfront treatment. If your cancer fits the pattern they’re studying, it may help researchers improve how future treatments are matched to patients.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.